Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

EVH - Evolent Health, Inc. Последние новости | Finranks

Home

EVH

E

Evolent Health, Inc. (EVH)

NYQ – Цена в реальном времени. Валюта: USD

2.21

-0.17 (-7.14%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

2.22

+0.01 (0.45%)

После закрытия: Mar 27, 2026, 7:57 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Evolent announces appointment of Archie Mayani as chief product officer

Evolent announces appointment of Archie Mayani as chief product officer

Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon. WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).

Evolent to Participate in Upcoming Investor Conferences

Evolent to Participate in Upcoming Investor Conferences

WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences. A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website.

Evolent Health: Cheap, Levered, But Ready To Rebound

Evolent Health: Cheap, Levered, But Ready To Rebound

Evolent Health, Inc. is rated a Buy, with turnaround momentum and risk/reward now favoring upside after recent operational and strategic shifts. EVH's Performance Suite model now covers ~90% of revenue, offering risk protection and greater earnings predictability, despite near-term profit headwinds from new contract launches. Oncology drives EVH's growth, with strong customer retention (>98%) and cost discipline via AI automation and workforce efficiencies delivering $20M+ in annualized savings.

Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript

Compared to Estimates, Evolent Health (EVH) Q4 Earnings: A Look at Key Metrics

Compared to Estimates, Evolent Health (EVH) Q4 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Evolent Health (EVH) Q4 Earnings Top Estimates

Evolent Health (EVH) Q4 Earnings Top Estimates

Evolent Health (EVH) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.02 per share a year ago.

Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model.

Видео

No Data

There is no data to display

Пресс-релизы

Evolent announces appointment of Archie Mayani as chief product officer

Evolent announces appointment of Archie Mayani as chief product officer

Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon. WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).

Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results

WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model.

Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08

Evolent Reports Inducement Award Under NYSE Listing Rule 303A.08

WASHINGTON, Jan. 2, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, announced that the Compensation Committee of Evolent's Board of Directors approved the grant of a one-time time-based restricted stock unit award covering 587,500 shares of Evolent Class A common stock, par value $0.01 per share (the "Inducement Award"), to Mr. Mario Ramos ("Mr.

Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden

Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden

WASHINGTON , Nov. 6, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, and American Oncology Network (AON), one of the nation's fastest-growing community oncology networks, today announced a new model enabling high-quality, more affordable, and connected cancer care — all without relying on prior authorization. The national partnership seeks to improve clinical decision-making by introducing quality-focused interventions, driving clinical insights through an innovative data and analytics platform, and rewarding providers for high-quality care.